China’s Top Regulator Upholds Tough Stance Against 'Redundant' Clinical Trials

PD-1 Overcrowding A Growing Issue

 
• By Dexter Jie Yan
  
clinical trial progress
Chinese regulator vows to continuously raise review requirements to prevent drain on clinical resources. • Source: Alamy
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from China

More from Asia